Jiang G, den Hertog J, Hunter T
Molecular Biology and Virology Laboratory, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.
Mol Cell Biol. 2000 Aug;20(16):5917-29. doi: 10.1128/MCB.20.16.5917-5929.2000.
We reported previously that the N-terminal D1 catalytic domain of receptor protein-tyrosine phosphatase alpha (RPTPalpha) forms a symmetrical, inhibited dimer in a crystal structure, in which a helix-turn-helix wedge element from one monomer is inserted into the catalytic cleft of the other monomer. Previous functional studies also suggested that dimerization inhibits the biological activity of a CD45 chimeric RPTP and the catalytic activity of an isolated RPTPsigma D1 catalytic domain. Most recently, we have also shown that enforced dimerization inhibits the biological activity of full-length RPTPalpha in a wedge-dependent manner. The physiological significance of such inhibition is unknown, due to a lack of understanding of how RPTPalpha dimerization is regulated in vivo. In this study, we show that transiently expressed cell surface RPTPalpha exists predominantly as homodimers, suggesting that dimerization-mediated inhibition of RPTPalpha biological activity is likely to be physiologically relevant. Consistent with our published and unpublished crystallographic data, we show that mutations in the wedge region of D1 catalytic domain and deletion of the entire D2 catalytic domain independently reduced but did not abolish RPTPalpha homodimerization, suggesting that both domains are critically involved but that neither is essential for homodimerization. Finally, we also provide evidence that both the RPTPalpha extracellular domain and the transmembrane domain were independently able to homodimerize. These results lead us to propose a zipper model in which inactive RPTPalpha dimers are stabilized by multiple, relatively weak dimerization interfaces. Dimerization in this manner would provide a potential mechanism for negative regulation of RPTPalpha. Such RPTPalpha dimers could be activated by extracellular ligands or intracellular binding proteins that induce monomerization or by intracellular signaling events that induce an open conformation of the dimer.
我们之前报道过,受体蛋白酪氨酸磷酸酶α(RPTPα)的N端D1催化结构域在晶体结构中形成对称的抑制性二聚体,其中一个单体的螺旋-转角-螺旋楔形元件插入另一个单体的催化裂隙中。先前的功能研究还表明,二聚化抑制了CD45嵌合RPTP的生物学活性以及分离的RPTPσ D1催化结构域的催化活性。最近,我们还表明,强制二聚化以楔形依赖的方式抑制全长RPTPα的生物学活性。由于缺乏对RPTPα二聚化在体内如何被调控的了解,这种抑制的生理意义尚不清楚。在本研究中,我们表明瞬时表达的细胞表面RPTPα主要以同源二聚体形式存在,这表明二聚化介导的对RPTPα生物学活性的抑制可能具有生理相关性。与我们已发表和未发表的晶体学数据一致,我们表明D1催化结构域楔形区域的突变以及整个D2催化结构域的缺失独立地降低但并未消除RPTPα同源二聚化,这表明两个结构域都至关重要地参与其中,但对于同源二聚化都不是必需的。最后,我们还提供证据表明RPTPα胞外结构域和跨膜结构域都能够独立地同源二聚化。这些结果使我们提出一个拉链模型,其中无活性的RPTPα二聚体通过多个相对较弱的二聚化界面得以稳定。以这种方式进行的二聚化将为RPTPα的负调控提供一种潜在机制。这种RPTPα二聚体可以被诱导单体化的细胞外配体或细胞内结合蛋白激活,或者被诱导二聚体开放构象的细胞内信号事件激活。